依达拉奉联合尼莫通治疗急性脑梗死疗效观察

Effectiveness of edaravone combined with nimodipine on patients with acute cerebral infarction

目的研究依达拉奉(Edaravone,EDA)联合尼莫通(Nimoldipine,NMP)对急性脑梗死(acute cerebral infarction,ACI)患者的疗效及对神经功能缺损评分(Neural function defect score,NFDS)的影响。方法选取我院2010-07—2013-07就诊的180例ACI病患,随机分成3组,每组60例。EDA组只给予EDA治疗,NMP组只给予NMP治疗,联合组给予EDA联合NMP治疗。比较3组治疗前后NFDS变化及疗效。结果 3组在治疗后NFDS评分都显著下降,其中联合组治疗后NFDS评分为(8.18±2.12)分下降程度最大,其次是EDA组(11.86±2.27)分,最次为NMP组(14.22±2.52)分。联合组愈显率为73.33%(44/60),总有效率是91.67%(55/60),较EDA组的48.33%(29/60),76.67%(46/60),以及NMP组的43.33%(26/60),73.33%(44/60)明显升高,差异均具有统计学意义(均P<0.05)。结论 EDA联合NMP治疗ACI,能有效改善病患NFDS评分,疗效显著,值得推荐。

Objective tostudytheeffectivenessofedaravone（EDA）combinedwithnimodipine（NMP）onpatientswitha-cute cerebral infarction（ACI） and their effects on the nerve function deficit score （NFDS）.Methods 108 cases of patients with ACI in our hospital from July 2010 to July 2013 were randomly divided into three groups. EDA group was treated with EDA , NMP group was treated with NMP ,combined group was treated with EDA and NMP. The clinical effectiveness and NFDS changes of three groups were compared.Results The NFDS of three groups after treatment were significantly decreased. The NFDS score of the combined group after treatment [（8.18 ± 2.12）piont] was the most obviously declined ,followed by EDA Group [（11.86 ± 2.27）piont] ,and then NMP Group [（14.22 ± 2.52）piont].The combined group’s markedly effective rate [73.33% （44/60）] ,the total efficiency [91.67% （55/60）] were significantly higher than EDA group’s [48.33% （29/60） , 76.67% （46/60）];NMP group’s [43.33% （26/60） ,73.33% （44/60）].The differences were statistically significant （P〈0.05）.Conclusion EDA combined with NMP can effectively improve NFDS score of patients with ACI and is worthy of recom-mendation.